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Summary. Functional deficiency or absence of the human
von Willebrand factor (VWF)-cleaving protease (VWF-cp),
recently termed ADAMTS-13, has been shown to cause
acquired and congenital thrombotic thrombocytopenic pur-
pura (TTP), respectively. As a first step towards developing
a small animal model of TTP, we have cloned the complete
(non-truncated) murine Adamts-13 gene from BALB/c mice
liver poly A+ mRNA. Murine ADAMTS-13 is a 1426-
amino-acid protein with a high homology and similar
structural organization to the human ortholog. Transient
expression of the murine Adamts-13 cDNA in HEK 293
cells yielded a protein with a molecular weight of approxi-
mately 180 kDa which degraded recombinant murine VWF
(rVWF) in a dose-dependent manner. The cleavage products
of murine rVWF had the expected size of 140 and 170 kDa.
Murine ADAMTS-13 was inhibited by EDTA and the
plasma from a TTP patient.
Keywords: ADAMTS-13, thrombotic thrombocytopenic pur-
pura, von Willebrand factor, von Willebrand factor-cleaving
protease.
Introduction
Von Willebrand factor (VWF) is a multimeric plasma
glycoprotein with two distinct biological functions. First, it
is required for platelet adhesion and platelet aggregation to
sites of vascular damage, and second, it acts as a carrier
protein for blood-clotting factor VIII in the circulation
[1–3]. Only the largest VWF multimers are hemostatically
active and can effectively mediate platelet adhesion, partic-
ularly under the high shear stress conditions of the arterial
capillary system [4–6]. To stop bleeding, secretion of very
high-molecular-weight VWF, so-called unusually large
VWF (ULVWF) by endothelial cells at the site of vascular
injury is therefore of physiological importance. Downstream
of the injury site, however, the uncontrolled presence of
ULVWF can have severe consequences. If the degradation
of VWF is impaired, persistent ULVWF multimers can, by
high-affinity interaction with platelet receptors such as
GP1b, agglutinate platelets at sites with high levels of shear
stress and thereby promote the risk of thrombosis [7]. The
disease associated with the formation of platelet and VWF-
rich thrombi is life threatening and has been termed
thrombotic thrombocytopenic purpura (TTP). Clinical
symptoms of TTP include microangiopathic hemolytic
anemia, thrombocytopenia, fluctuating neurological impair-
ment, renal dysfunction and fever [8–10].
A plasmatic metalloprotease, originally termed VWF-clea-
ving protease (VWF-cp) is associated with VWF degradation
[11,12], and a deficiency of VWF-cp has been found in plasmas
of patients with familial relapsing TTP as well as the presence
of an antibody inhibitor to VWF-cp in patients diagnosed with
acquired TTP [13–16].
N-terminal sequencing of purified plasmatic VWF-cp
[17,18] as well as conventional cDNA cloning [19,20] and
a sophisticated positional cloning approach [21] identified
the gene encoding for human VWF-cp as a member of a
multidomain metalloprotease family called ADAMTS (a
disintegrin-like and metalloprotease with thrombospondin
type 1 repeat motifs [22,23]). According to the suggested
nomenclature of ADAMTS proteins, human VWF-cp was
designated ADAMTS-13. Expression studies showed func-
tional activity of recombinant ADAMTS-13 (rADAMTS-13)
[24,25] in plasma towards human VWF as a substrate.
ADAMTS-13 was identified as the enzyme inhibited by the
IgG fraction of TTP patients’ plasma, suggesting a causal
relation between ADAMTS-13 inhibitory antibodies and
TTP. Human rADAMTS-13 was also shown to correct the
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deficiency of VWF-degrading capacity in plasma from
patients diagnosed with hereditary TTP [26].
Tremendous progress has been made in explaining the
causal relations that ultimately lead to clinically relevant
TTP [27]. However, many questions about the cause of TTP
are still unanswered and cannot easily be addressed in
humans. A small animal model of TTP would therefore be
of great clinical interest. Despite the known limitations of
animal models, the availability of an animal model faithfully
mimicking human TTP would greatly facilitate the devel-
opment of treatment modalities other than plasma exchange
or plasma infusion.
The putative sequence of the murine Adamts-13 gene has
recently been predicted by automated computational analysis
(NCBI GenBank: AB_095445) and the full-length cDNA
sequence was determined [28], but functional activity of the
murine ADAMTS-13 gene product has not yet been verified.
A first step towards development of a murine model for TTP
is the cloning and characterization of the murine ortholog to
the human ADAMTS-13. In this study we describe the cloning
of the complete (non-truncated) murine Adamts-13 cDNA
sequence, an Adamts-13 mRNA expression analysis, the
expression of the murine recombinant ADAMTS-13
(rADAMTS-13) in eukaryotic cells and the initial functional
characterization of the activity of the mouse enzyme towards
murine recombinant VWF (rVWF).
Materials and methods
Database searches
Nucleic acid sequence information was obtained by searching
the NCBI GenBank (http://www.ncbi.nlm.nih.gov/). The
SMART program (http://smart.embl-heidelberg.de) and Clu-
stalW (http://www.ebi.ac.uk/clustalw/) were used for analysing
domain structures. Amino acid sequences were compared by
use of the EMBL protein database (http://www.ebi.ac.uk/
clustalw) and AlignX (Vector NTI Suite 8.0; InforMax,
Frederick, MD, USA).
Reverse transcription of poly A+ RNA
To obtain long transcripts, 3 lg of poly A+RNA from liver of
BALB/c mice (Stratagene, San Diego, CA, USA) was heated
for 5 min at 64 C and reverse transcribed for 1.5 h at 42 C
with the Expand RT kit from Roche (Roche Molecular
Biochemicals, Mannheim, Germany) in a final volume of
120 lL with concentrations of reagents according to the
instructions of the manufacturer using 100 pmol of primer
spdT consisting of a poly dT part, a randomly chosen specific
sequence (MC18) and twoNNat the 3¢ end for specific fixation
of the primer (Table 1).
Polymerase chain reaction
All purifications were carried out according to the supplier
protocols. ComplementaryDNAsolution (1 lL)was subjected
to polymerase chain reaction (PCR) using a thermally activated
DNA polymerase (FastStart Taq DNA Polymerase from
Roche Molecular Biochemicals, or HotStar Taq polymerase
fromQiagen, Hilden, Germany). The PCRwas carried out in a
total volume of 50 lL containing 1 U of the polymerase in the
buffer supplied by the manufacturer (with addition of GC
solution as recommended), 200 lM of dNTP and 50 pmol each
of forward and reverse primer (Table 1). The samples were
overlaid with mineral oil, incubated for 4 min at 95 C (14 min
for HotStar polymerase) and then amplified for 45 cycles in a
TRIO-Thermoblock (Biometra, Göttingen, Germany) with the
following cycle profile: 50 s at 95 C, 50 s at 62 C, and
1–6 min at 72 C (1 min extension for approx. 1 kb of DNA).
The samples were then fractionated on a 1% agarose gel
stained with ethidium bromide.
Sequencing of PCR products
For each primer pair multiple independently created PCR
products were sequenced on an Applied Biosystems Model
373A Sequencer (Applied Biosystems, Foster City, CA, USA)
using the cycle sequencing method with dye terminators (BIG
Table 1 Sequences of primers used for polymerase chain reaction
Name Sequence Remark
6844 5¢-TTCTGCACCTGGAACTCCTG-3¢ Expr. PCR forward
6956 5¢-TAGAGGCCAGGCTGTGCCATCAGCTGG-3¢ Expr. PCR reversed
6957 5¢-ACCTGGGCTGCAGTCAGGACTTA-3¢ Expr. PCR forward
6963 5¢-GGAGTGCTGCTACGGTACTGGAGTC-3¢ Expr. PCR forward
6964 5¢-ATGGTCCAATACTCGCCCTGGA-3¢ Expr. PCR reversed
6992 5¢-ACAAGCCTGCGTGTTGCATC-3¢ Expr. PCR reversed
7577 5¢-GAGCGAATTCGCCGGCCACCATGAGCCAGCTTTGCCTGTG-3¢ EcoRI forward 5¢
7578 5¢-GAGCGGTACCGTGAGATACTAGTCTTCCCTGC-3¢ SpeI reversed 5¢
7589 5¢-GACAGGTACCACTAGTATCTCACCCAACACC-3¢ SpeI forward 3¢
7580 5¢-GCAGTTCCATGGCTCGAGGCTAAAGTTGCATACTCC XhoI reversed 3¢
spdT 5¢-GAGCAAATTCCTGTACTGAC (T)30 NN-3¢ Production of cDNA
MC18 5¢-GAGCAAATTCCTGTACTGAC-3¢ Specific part of spdT
7455 5¢-GCAGCAGGTGCTCTACTGGGAGTC-3¢ Expr. PCR forward
7635 5¢-CAGCCCTTCTGCACCTGGAAAAGGTCACTA-3¢ Expr. PCR reversed
Functional expression of murine ADAMTS-13 1065
 2005 International Society on Thrombosis and Haemostasis
Dye Terminator Cycle Sequencing Ready Reaction; Applied
Biosystems) and the same primers as used in the PCR. The
chromatograms were aligned and assembled to the complete
gene sequence using the Sequence Editor (SeqEd; Applied
Biosystems).
N-terminal amino acid sequence analysis
The VWF cleavage fragments generated by incubation with
murine rADAMTS-13were separatedby reducingSDS–PAGE
and were electrotransferred to a Sequi-blot polyvinylidene
difluoride (PVDF) membrane (BioRad, Hercules, CA, USA)
according to Plaimauer et al. [25]. N-terminal amino acid
sequence analysis of the excisedproteinbandswas carried out at
Toplab (Martinsried, Germany).
Construction of a murine Adamts-13 cDNA clone
The cDNA was first PCR amplified with a variety of
primers specific for some of the putative exons. To reduce
cloning steps to a minimum number, primer combinations
were tested to obtain the longest possible PCR products.
Finally, two reverse transcriptase (RT)-PCR products
obtained from primers 7577/7578 for the 5¢ end and 7580/
7589 for the 3¢ end (Table 1) were necessary to obtain a
cDNA construct containing the whole murine Adamts-13
sequence. Primer 7577 contains an EcoRI restriction enzyme
recognition sequence, the Kozak sequence, to enhance
translation [29] and an AUG codon, and primer 7580 a
XhoI site. Primers 7578 and 7589 have a SpeI site, which
was created internally without altering the amino acid
sequence. The 5¢-Adamts-13 PCR fragment obtained from
primers 7577/7578 and the 3¢ Adamts-13 fragment from
primers 7589/7580 were cloned into the pCR2.1-TOPO
vector (TOPO TA cloning kit; Invitrogen, Lofer, Austria).
The plasmid containing the 5¢ end of Adamts-13 was digested
with SpeI, treated with calf intestinal phosphatase (CIP) and
the 3¢ end of Adamts-13 cleaved by SpeI was ligated into
this site. An EcoRI/XhoI fragment containing the com-
plete murine Adamts-13 cDNA was then subcloned into
pcDNA3.1 (Invitrogen).
Multi-tissue Northern blot
A 768-bp probe (derived from the 5¢ end) was excised from
the Adamts-13 cDNA construct by EcoRI/PmlI digestion,
separated on an agarose gel and purified with the Qiagen gel
extraction kit (Qiagen). The Adamts-13 probe and a b-actin
cDNA control probe were labeled with the random-
primed DNA labeling kit (Roche) using a-32P dCTP
(6000 Ci mmol)1) and nick columns (Amersham Biosciences,
Uppsala, Sweden) for removal of free nucleotides according
to the instructions of the suppliers. A commercially available
multitissue Northern blot (MTN, poly A+ RNA from
BALB/c mice; BD Biosciences, Erembodegem, Belgium)
was then hybridized overnight at 60 C in ExpressHyb
hybridization solution (Clontech, Palo Alto, CA, USA),
washed twice for 20 min at room temperature with 2 · SSC,
0.05% SDS, once for 20 min at 50 C with 0.1% SSC, 0.1%
SDS and then exposed to a X-ray film. It has to be noted
that for the b-actin control the presence of a single 2.0-kb
band is confirmed for all lanes and a 1.8-kb actin isoform
may predominate in heart, skeletal muscle and testis lanes.
Multi-tissue PCR gene expression panel
For studying gene expression in different tissues by RT-PCR, a
BD MTCTM cDNA panel from BALB/c mice was purchased
from BD Biosciences (Palo Alto, CA, USA). The cDNAs were
diluted 1 : 3, 1 : 10, 1 : 33, and 1 : 100. Then PCR was
performed with 50 pmol each of primer pairs 6844 (forward)/
6956 (reversed) and 7455 (forward)/7635 (reversed) (Table 1)
or primers specific (supplied by the manufacturer) for the
control gene glyceraldehyde 3-phosphate dehydrogenase
(G3PDH) following standard PCR procedures with the
following cycle profile: 94 C for 2 min; five cycles at 94 C
for 30 s and 72 C for 5 min; five cycles at 94 C for 30 s and
70 C for 5 min; 35 cycles at 94 C for 30 s, 62 C for 30 s and
70 C for 5 min.
For embryonic tissues (FVB strain) the mouse Rapid-
ScanTM gene expression panel was purchased from Origene
Technologies, Inc. (Rockville, MD, USA) and used according
to the supplier’s instructions. Briefly, each cDNA is diluted into
96 wells to a series of four concentrations (labeled 1000 ·,
100 ·, 10 · and 1 ·), with the lowest concentration (1 ·) being
approximately 1 pg cDNA/well. According to the supplier’s
instructions, 25 lL of PCR premix including 50 pmol of
forward primer 7455 and reversed primer 7635 or forward
primer 6957 and reversed primer 6992 (Table 1) or primers
specific for the control b-actin gene (supplied by the manufac-
turer) were added to each well. The multiwell PCR plate was
covered, incubated on ice for 15 min, gently mixed and
transferred into the block of a 96-well thermal cycler. PCR was
performed as described above. The PCR products were
analyzed on a 1% agarose gel.
Transfection and cell culture of murine rADAMTS-13
The murine rADAMTS-13 construct was transiently expressed
in HEK 293 (human embryonic kidney fibroblasts; ATCC
CRL-1573) cells, routinely grown inDMEM/Ham’sF12 (1 : 1)
medium (Life Technologies, Lofer, Austria) supplemented with
10% fetal calf serum (full medium). Transient transfection was
carriedoutat85–95%confluenceusing lipofectamine2000 (Life
Technologies) according to the supplier’s protocol. At 24 h
post-transfectionmediumwas changed and serum-freemedium
wasapplied to the confluent cells for 24 h.Conditionedmedium
was collected, clarified by centrifugation and concentrated
20-fold using Amicon Centriprep YM-30 (Millipore, Bedford,
MA, USA) at 4 C. Control cell culture supernatant from
cells not transfected was prepared accordingly. The human
rADAMTS-13 was expressed as described [25].
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Western blot analysis
Recombinant ADAMTS-13 samples were reduced, denatured,
and resolved by SDS–PAGE on 4% stacking/6% separation
gels and visualized by Western blotting as described [30].
Recombinant ADAMTS-13 was detected using the monoclo-
nal antibody 242/H2, a subclone of 242/H1 generated as
described previously [25], together with alkaline phosphatase-
conjugated goat antimouse IgG (Sigma, St Louis, MO, USA)
as a detection antibody and 5-bromo-4-chloro-3-indolyl-phos-
phate/p-nitroblue-tetrazolium (BCIP/NBT) (Promega, Madi-
son, WI, USA) as substrate. Monoclonal antibody 242/H2 is
directed against the catalytic domain of human ADAMTS-13.
Expression of murine rVWF
The murine VWF expression plasmid was a generous gift
from D. Ginsburg (University of Michigan). The cDNA
encoding murine VWF was amplified by RT-PCR using
total lung RNA prepared from CASA/Rk mice. The cDNA
was cloned into modified multiple cloning sites of the
pcDNA3.1 expression vector (Invitrogen), and is flanked by
NotI (5¢) and XbaI (3¢) sites. The assembled cDNA contains
an optimized Kozak sequence and a 3¢ myc epitope tag
(EQKLISEEDL), but does not contain the 5¢ or 3¢
untranslated regions. Fidelity of the PCR was verified by
direct DNA sequencing of the entire insert. The rVWF
constructs were then transiently expressed in HEK 293 cells
as described above for murine rADAMTS-13.
Assay for VWF-cleaving activity
The assay for VWF-cleaving activity was done as described
[31]. Cell cultures were washed twice with 10 mL PBS before
adding serum-free medium. Then cell culture supernatant from
1.5 · 106 HEK 293 cells mL)1 containing murine rADAMTS-
13 was diluted 1 : 20, 1 : 40, 1 : 80 or 1 : 160 in 50 lL 5 mM
Tris–HCl pH 8.0, 12.5 mM BaCl2, 1 mM Pefabloc SC (Roche)
followed by 5 min incubation at 37 C for activation of the
protease. BaCl2 was included because it was found to be a
strong activator for the proteolysis of VWF multimers by
ADAMTS-13 [11]. Twenty-five microliters of 20-fold concen-
trated conditioned medium (approximately 100 ng) from cells
transiently expressing murine rVWF in 5 M urea, 5 mM Tris–
HCl pH 8.0 was added and incubated overnight at 37 C. The
reaction was stopped by adding EDTA to a final concentration
of 23.5 mM. In the control experiments the cell culture
supernatants were incubated with 50 mM EDTA or 0.25 lL
of a plasma from a TTP patient with anti-ADAMTS-13
inhibitory antibodies or 9 lg purified IgG from normal human
plasma using protein G Sepharose according to Plaimauer
et al. [25] prior to the addition of rVWF. VWFmultimers were
analyzed by SDS electrophoresis on 1.4% SeaKem HGT(P)-
Agarose (Biozym Diagnostics, Oldenburg, Germany) as
described [32], followed by immunoblotting and detection with
a-VWF antibody (Dako, Glostrup, Denmark) and goat
antirabbit antibody coupled to alkaline phosphatase and
BCIP/NBT (Promega).
Results
Cloning of the murine ADAMTS-13 and comparison of
amino acid sequence
Poly A+ RNA from liver of BALB/c mice was reverse
transcribed, the resulting cDNA solution subjected to PCR and
the entire murine Adamts-13 cDNA sequence assembled in a
two-step procedure (seeMaterials andmethods). Our RT-PCR
procedure yielded a cDNA clone with the deduced murine
ADAMTS-13 amino acid sequence identical to the pub-
lished sequence (NCBI GenBank: AB_095445). The murine
ADAMTS-13 precursor polypeptide consists of 1426 amino
acid residues and is structurally similarly organized to that of
the human counterpart (1427 amino acids, Fig. 1A).
Murine ADAMTS-13 has the typical multidomain structure
also found in human ADAMTS-13 [19]. A signal peptide
sequence of 37 amino acids (human 33 amino acids) is followed
by an exceptionally short propeptide of 39 amino acids (human
41 amino acids), which is terminated by a typical proprotein
convertase site [33], RRRR (human RQRR). The metallo-
protease domain contains a conserved active site sequence
consisting of the HEXXHXXGXXHD motif typical for
reprolysine type proteases [34], the conserved M253 residue
(human M249) in a proposed Met-turn, and residues E85,
D175, C285, and D289, which are predicted to coordinate a
structural Ca2+ ion (human E83, D173, C281, and D284). The
first thrombospondin type 1 region (TSP1-1), with a 50%
similarity to murine thrombospondin type 1 repeats (murine
TSP1, NCBI GenBank: NP_035710), is found downstream of
the disintegrin-like domain. This region is followed by the
murine equivalent to the human cysteine-rich/spacer domain
containing a RGD sequence putatively mediating integrin
interactions [35]. Downstream of the cysteine-rich/spacer
domain, seven additional TSP1 repeats (TSP1-2 to TSP1-8)
are present. As with human ADAMTS-13, the murine
counterpart contains two CUB domains at its C-terminus, a
structural feature which has not so far been found in other
ADAMTS proteases. Murine and human ADAMTS-13 have
an overall similarity of 69% at the amino acid level. Not
unexpectedly, high homologies are observed in functional
domains such as the metalloprotease- (77%), the disintegrin-
like (81%), and the cysteine-rich (80%) domain. The individual
domain with the highest degree of conservation is TSP1-1
(88%,Table 2) suggesting an important physiological function.
Homologies between the TSP1 regions of human and mice
vary between 88% (TSP1-1) and 37% (TSP1-6) (Table 2).
ADAMTS-13 has eight asparagines predicted as potential
N-linked glycosylation sites at residues 144, 148, 557, 564, 584,
619, 834, 1057 (humanADAMTS-13 has 10 potential N-linked
glycosylation sites at residues 142, 146, 552, 579, 614, 667, 707,
828, 1235, 1354). Thus the positions 144 and 148 (metallo-
protease domain), position 557 (cysteine-rich domain),
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positions 584 and 619 (spacer domain) and 834 (TSP1-4
domain) are conserved. Both proteins contain the sequence
motifWXXW in the TSP1-1 region, which is oftenmodified by
C-mannosylation [19,36]. With the exception of TSP1-4
(human andmouse) and TSP1-6 (mouse only) in both proteins,
all TSP1 elements contain the conserved sequence motif
CSX(S/T)CG usually modified by O-glycosylation of the
disaccharide Glc-Fuc [19,36].
Interestingly, some amino acid exchanges reported to
constitute human ADAMTS-13 single-nucleotide polymor-
phisms (SNPs) [21,24,26,37] can be found at the equivalent
position in the mouse sequence, e.g. residues W7, E448 and
V900 in the murine wild-type ADAMTS-13 sequence
correspond to the reported human SNPs R7W, Q448E
and A900V.
A comparison of the degree of homology between murine
ADAMTS-13 and all other murine members of the ADAMTS
family described to date as well as with the human ADAMTS-
13 sequence is shown in Fig. 1B. The phylogenic tree for the
respective human ADAMTS proteins is very similar to the
murine counterparts [38–41].
Expression pattern of the murine Adamts-13 mRNA
The expression pattern of the murine Adamts-13 mRNA was














Fig. 1. (A) Amino acid sequence comparison of human ADAMTS-13 and murine ADAMTS-13. Start and end of the signal peptide, propeptide,
metalloprotease with active site, disintegrin-like domain, thrombospondin type 1 motifs (tsp1), the cysteine-rich domain, spacer, and cub domains are
indicated by arrows. (B) Phylogenic tree of themouseADAMTS family. The dendogram shows the relation of the complete sequence of murineADAMTS
proteins and human ADAMTS-13.
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commercially available multitissue Northern filter containing
RNA derived from heart, brain, spleen, lung, liver, skeletal
muscle, kidney, and testis tissue (Fig. 2A). With a probe
specific for the 5¢ end the filter showed expression of a single
mRNA in the liver (lane 5). Probes specific for the 3¢ end led to
no visible band (data not shown).
In order to verify and to expand this result we used a
commercially available cDNA panel of the BALB/c strain to
analyze mRNA expression by a more sensitive PCR approach.
The PCRs were repeated with two different primer pairs
specific for the 5¢ part of Adamts-13 (Table 1), five times each.
Adamts-13 expression was found to be consistently high in
liver, medium in lung and spleen, low in skeletal muscle and
undetectable in heart, brain, kidney and testis (Table 3).
Expression of the control gene G3PDH was found to be
equally high in all tissues down to the lowest dilutions used in
the assay (data not shown).
Embryonic-tissue PCR gene expression panel
To investigate the levels of Adamts-13-specific mRNA accu-
mulation in embryonic tissue of mice, Mouse rapid-scan gene
expression panelswere used (seeMaterials andmethods). Each
of these panels contained normalized amounts of cDNA
isolated from mouse embryos (FVB strain) at a specific age.
The quality of the cDNAs was checked by amplification of the
b-actin gene as recommended by the manufacturer (Fig. 2E).
Serial dilution of the cDNAs and subsequent amplification of
Adamts-13-specific transcripts by PCR using Adamts-13-
specific primers gave a good estimate of the relative amount
of Adamts-13-specific cDNA within the embryonic tissue of a
certain age. To select for full-length transcripts the scan was
carried out with a forward primer (7455, Table 1) located in the
second CUB domain and a reversed primer (7635, Table 1)
located between the stop codon and the poly T sequence. The
PCR resulted in a 262-bp fragment. To probe additionally for
the truncated form ofAdamts-13 [28], primers 6963/6964 (PCR
product 383 bp) located in the metalloprotease region were
used. ADAMTS-13-specific mRNA increases steadily with the
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Fig. 2. RNA expression pattern of the murine Adamts-13. The expression
pattern of the murine Adamts-13 was examined using a multitissue
Northern blot. (A) Lane 1, Heart; lane 2, brain; lane 3, spleen; lane 4, lung;
lane 5, liver; lane 6, skeletal muscle; lane 7, kidney; lane 8, testis. A
a-32P-labeled 754-bp EcoRI/PmlI fragment derived from the ADAMTS-
13 N-terminus was used as a probe. (B)Multitissue Northern blot analysis
with a-32P-labeled b-actin cDNA as control probe. Lane 1, Heart; lane 2,
brain; lane 3, spleen; lane 4, lung; lane 5, liver; lane 6, skeletal muscle; lane
7, kidney; lane 8, testis. (C) Agarose gel analysis of polymerase chain
reaction (PCR) fragments (specific for the non-truncated form of
Adamts-13) generated from embryonic tissue derived from the commer-
cially available Mouse Rapid-ScanTM gene expression panel. Four serial
dilutions (10-fold) of cDNA prepared from mouse embryonic tissue were
PCR amplified. E, Embryo tissue, 8.5 days, 9.5 days and 19 days old,
respectively; 1000 ·, highest concentration; 1 ·, lowest concentration of
the cDNA. (D) PCR specific for the truncated form of Adamts-13.
(E) PCR specific for b-actin as control for integrity of cDNA.
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between the two primer pairs. The relative abundance of
Adamts-13 mRNA is highest at an embryo age of 19 days
(Fig. 2C, lanes 9, 10, 11, and Fig. 2D, lanes 9–12 are positive)
followed by day 9.5 (lanes 5 and 6 are positive) and day 8.5 (just
lane 1 is positive).Adamts-13mRNA levels were essentially the
same for an embryo age of 9.5 and 12 days (data not shown).
Expression of murine rADAMTS-13 protein
The cDNA sequence ofAdamts-13was cloned in an eukaryotic
expression vector and murine ADAMTS-13 was transiently
expressed in HEK 293 cells. After 24 h, serum-free conditioned
media were analyzed by Western blotting. We detected the
expected band reactive with the antihuman ADAMTS-13
monoclonal antibody 242/H2 [25] at a molecular weight of
approximately 180 kDa (Fig. 3, lane 3) at the same size as
human rADAMTS-13 (Fig. 3, lane 2). In contrast to human
ADAMTS-13, a second band with a lower molecular weight
[42] putatively derived from a proteolytic processing event was
not observed with the murine rADAMTS-13.
Degradation of murine rVWF multimers by murine
rADAMTS-13
The biological activity of murine rADAMTS-13 was assayed
by its ability to degrade murine VWF multimers in vitro. The
murine VWF was transiently expressed in HEK 293 cells and
concentrated conditioned medium containing approximately
100 ng VWF was incubated with diluted cell culture superna-
tants of HEK 293 cells transfected with the murine Adamts-13
construct. In contrast to the control cell culture supernatant
transfected with the parental construct (Fig. 4, lane 2), the
supernatant containing murine rADAMTS-13 degraded the
rVWF multimers in a dose-dependent manner from 1 : 20 to
1 : 160 dilutions (Fig. 4, lanes 4–7). Other controls were the
addition of themetal ion-chelating agent EDTA (Fig. 4, lane 3)
and the addition of plasma from a TTP patient (Fig. 4, lanes
8–11). In both cases ADAMTS-13 activity was strongly
inhibited, whereas purified IgG derived from normal human
plasma did not inhibit the degradation (Fig. 4, lanes 12–15).
MurinerADAMTS-13alsodegradedhumanVWF,althoughat
a much higher protease-to-VWF ratio (data not shown). The
specificity of murine rADAMTS-13 was further characterized
by N-terminal amino acid sequence analysis of the cleavage
fragments of murine rVWF generated by incubation with
murine rADAMTS-13 (Fig. 5A,B).As expected, two fragments
with the N-terminal sequences SLSCRP and MVTGN corres-
ponding to the 140-kDa and the 170-kDa bands, respectively,
were obtained (Fig. 5A,B).The sequenceSLSCRP(S764–P770,
numbering according to Swiss-Prot: Q8CIZ8) was identical to
the region upstream of a putative Furin cleavage site (R763–
S764) that separates the murine VWF propeptide from the
mature VWF,whereas the sequenceMVTGN (M1606–N1610)
could be found C-terminal of the predicted ADAMTS-13
cleavage site Y1605–M1606. The murine rVWF preparation
contained also free VWF propeptide (Fig. 5A,B). The N-
terminal sequence of the approximately 100-kDa fragment was
TEKPRD, corresponding to the murine VWF propeptide
sequenceupstreamof thesignalpeptidecleavage site (C22–T23).
Table 3 Semiquantitative analysis of ADAMTS-13 expression in tissues
of BALB/c mice
Tissue 1 : 3 1 : 10 1 : 33 1 : 100
Heart – – – –
Brain – – – –
Spleen + +/– – –
Lung + +/– – –
Liver + + + –
Muscle +/– – – –
Kidney – – – –
Testis – – – –
Normalized first-strand cDNA was diluted as indicated and each
dilution was polymerase chain reaction (PCR)-amplified 10 times
independently. +, PCRs always positive; +/–, PCRs with mixed
results; –, PCRs always negative.
180
110
kDa M 1 2 3 
Fig. 3. Western blot of transiently expressed murine rADAMTS-13.
Conditioned media from HEK 293 cells transiently expressing murine
rADAMTS-13 (equivalent to approximately 2.4 · 105 cells) were loaded
on SDS-polyacrylamide gels, blotted to nitrocellulose and immunostained.
M, Marker proteins, 1 ¼ vector control, 2 ¼ human rADAMTS-13 from
HEK 293 cells, 3 ¼ murine rADAMTS-13 from HEK 293.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Fig. 4. Activity assay for murine rADAMTS-13 by vonWillebrand factor
(VWF) multimer analysis. HEK 293 cell culture supernatant containing
murine rADAMTS-13 diluted 1 : 20 [lane 3 with 50 mM EDTA, lane 4
supernatant alone, lane 8 with thrombotic thrombocytopenic purpura
(TTP) plasma, lane 12 with purified IgG from normal human plasma],
1 : 40 (lane 5, lane 9 with TTP plasma, lane 13 with purified IgG from
normal human plasma), 1 : 80 (lane 6, lane 10 with TTP plasma, lane 14
with purified IgG from normal human plasma) or 1 : 160 (lane 7, lane 11
with TTP plasma, lane 15 with purified IgG from normal human plasma)
and cell culture supernatant of cells not transfected diluted 1 : 20 (lane 2),
were incubated with 25 lL (approximately 100 ng) murine rVWF and
the cleavage analyzed by VWF-multimer gel electrophoresis. Lane 1,
rVWF without any additions.
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Discussion
Human ADAMTS-13 plays a pivotal role in the development
of acquired as well as in hereditary TTP [19,21,24–26]. Both
diseases are associated with the persistence of ULVWF and,
after a yet uncharacterized precipitating event, the formation of
platelet- and VWF-rich thrombi in the arterial vascular tree. A
small animal model for TTP is still lacking. Despite the obvious
limitations of animal studies, an animal model would allow us
to study the development of the disease and would also be
highly beneficial for the development of a treatment strategy
other than plasma infusion or plasma exchange. As a first step
towards developing a suitable animal model, we were interested
in the cloning and biochemically characterizing the murine
ADAMTS-13 protein.
From computer-assisted searches of the available mouse
genomic sequences, the murine ADAMTS-13 protein sequence
and structure was already predicted (NCBI GenBank:
AB_095445). We obtained the full-length murine Adamts-13
cDNA in a two-step procedure from a BALB/c mouse liver
mRNA preparation. Our clone matched exactly the sequence
predicted by computational analysis. Not unexpectedly, the
precursor polypeptide was very similar to the human counter-
part in size and structural organization, and had an overall
similarity on the amino acid level of 69%. As with human
ADAMTS-13 [19,33], compared with other human ADAMTS
proteins murine ADAMTS-13 is significantly different from
other members of the murine Adamts protease family
(e.g. exceptionally short propeptide, two CUB domains at
carboxyl terminus), making it the most divergent member of
the murine group.
Strain-specific variants of the mouse Adamts-13 gene were
recently identified and an intracisternal A-particle insertion was
found in the intron 23 of several mouse strains, including
BALB/c mice [28]. This insertion was proposed to lead to a
truncated version (1037 amino acids) of ADAMTS-13 because
of the introduction of an in frame stop codon by splicing exon
23 to the pseudo-exon 24.
The aim of our study was to clone and express the non-
truncated form of the murine ADAMTS-13. By using the
appropriate primer combination we have been able to clone the
complete murine Adamts-13 gene from a poly A+ RNA
preparation derived from the liver of BALB/c mice. A
Northern blot analysis of mRNA derived from various tissues
from BALB/c mice with a probe specific for the 5¢ end showed
a single band around 4 kb in liver tissue as described [28].
Because the same Northern blot treated with a probe specific
for the 3¢ end gave no signal, this band probably corresponds to
the truncated form of murine ADAMTS-13. However,
although derived from BALB/c mice, the sources of the
mRNA for the Northern blot and for the cDNA cloning were
not identical. Our results therefore allow for the interpretation
that either our extremely sensitive PCR method might be
responsible for successful amplification of residual amounts of
full-length Adamts-13 mRNA, or subpopulations of BALB/c
mice might exist that do not harbor the intracisternal A particle
(IAP).
Apart from the tissue distribution of ADAMTS-13 expres-
sion in adult tissues, we were also interested in the analysis of
ADAMTS-13 expression in the developing mouse embryo.
Using a semiquantitative PCR-based method, we could show
that there is a steady increase of Adamts-13mRNA (truncated
and non-truncated form, FVB strain) detectable in the growing
embryo, reaching highest levels in embryonic tissues of 19 days
of gestation. It should be noted that these results do not
reveal tissue-specific differential expression during embryonic
development.
Transiently transfected HEK 293 cells expressed the murine
Adamts-13 cDNA as a protein of approximately 180 kDa.
Murine ADAMTS-13 was detected by Western blot analysis
using the antihuman ADAMTS-13 protease domain mono-
clonal antibody 242/H2 [25] as a detection antibody. Unlike
human ADAMTS-13 [42], the murine enzyme does not show
any C-terminal proteolytic truncation when secreted in
the supernatant of HEK 293 cells. Moreover, the murine
rADAMTS-13 is functionally active, as clearly shown by its
ability to degrade recombinant murine VWF multimers in a
dose-dependent manner. The cation chelator EDTA and
plasma from a TTP patient inhibited the degradation of
VWF multimers completely. Furthermore, the murine rVWF
was cleaved by murine rADAMTS-13 at the appropriate site
(amino acid positions Y1605 and M1606), thus generating the
expected cleavage fragments.
In summary, we have cloned and functionally characterized
the murine ADAMTS-13 protein, which promises to be a
helpful tool to explain the physiological role of ADAMTS-13
as well as to gain more insight into the pathopysiological





















Fig. 5. N-terminal amino acid sequence analysis of murine recombinant
von Willebrand factor (rVWF) fragments. Murine rVWF was incubated
with murine rADAMTS-13, the cleavage fragments were separated by
reducing SDS–PAGE electrotransferred polyvinylidene difluoride
(PVDF) membrane, and the N-terminal amino acid sequence was deter-
mined. To characterize the murine VWF propetide present in the rVWF
preparation, the N-terminal sequence of the 100-kDa fragment was also
determined. (A) Schematic drawing of the expected rVWF-specific bands
after processing of propetide containing VWFwith Furin and ADAMTS-
13. The N-terminal amino acids are given in bold letters. (B)Western blot
of the three analyzed bands. Lane 1, Molecular weight marker; lane 2,
negative control (buffer and rVWF); lane 3, murine rADAMTS-13 and
rVWF.
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mechanisms leading to an autoimmune response to
ADAMTS-13. Moreover, the availability of recombinant
murine ADAMTS-13 will be instrumental for the development
of an animal model for TTP, and the explanation of the specific
role of VWF in arterial thrombosis.
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